Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Linaclotide (Linzess)
Beginner tier: 145 mcg, daily · FDA label
Also known as: Linzess (US), Constella (EU), MD-1100
Roughly 34% of IBS-C patients hit the FDA composite response endpoint on linaclotide at 290 mcg daily, with bowel improvements showing up within 24 hours of the first capsule. Linaclotide (brand name Linzess) is a 14-amino-acid oral peptide that activates guanylate cyclase-C receptors in the intestinal lumen, triggering both fluid secretion and visceral pain reduction through two distinct cGMP pathways. That said, about two-thirds of patients don't meet the full responder threshold, and diarrhea affects 14 to 20% of users. The drug has three FDA-approved dose levels (72, 145, and 290 mcg) covering chronic idiopathic constipation, IBS-C, and pediatric functional constipation.
What Is Linaclotide (Linzess)?
Fourteen amino acids. Three disulfide bonds. One of the only peptide drugs on the planet designed to survive your stomach acid and work without ever reaching your bloodstream.
Linaclotide (Linzess, Constella; CAS 851199-59-2) is a first-in-class guanylate cyclase-C agonist, structurally related to the endogenous hormones guanylin and uroguanylin. The FDA approved it in 2012 for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). It binds GC-C receptors on intestinal epithelial cells, raising intracellular cGMP. That activates CFTR chloride channels, pulling water into the intestinal lumen and speeding transit. A second pathway exports cGMP to the submucosal space, where it dials down visceral pain signaling through afferent nerve modulation.
The important Phase 3 trial by Chey and colleagues (n=800+)[1] ran 26 weeks and landed on a 33.7% composite responder rate versus 13.9% for placebo. The NNT is 5 to 8, depending on the trial. For CIC, a separate Phase 3 program confirmed efficacy at 145 mcg with an NNT of 6 to 10.
Real-world use tracks closely with the clinical data. Across 500+ Reddit threads in r/ibs and r/Constipation and roughly 900 Drugs.com reviews (6.7 out of 10), the pattern is consistent: rapid onset of bowel relief within 24 to 48 hours, meaningful pain reduction by week 2, but diarrhea as the dominant complaint at 290 mcg. Community users have independently figured out what the pharmacology predicts; GC-C receptor occupancy is near-maximal at 72 to 145 mcg, so lower doses often achieve comparable constipation relief with less GI disruption.
How Linaclotide (Linzess) Works
Linaclotide mirrors the body's own guanylin and uroguanylin peptides, but with a tighter, protease-resistant conformation locked in by three disulfide bonds (Cys1-Cys6, Cys2-Cys10, Cys5-Cys13). Once the capsule dissolves, the peptide reaches the apical surface of intestinal epithelial cells and binds GC-C receptors directly.
GC-C activation converts GTP to cyclic guanosine monophosphate (cGMP) inside the cell. Raised cGMP switches on cGMP-dependent protein kinase II (PKG-II), which phosphorylates and opens the CFTR chloride channel. Chloride and bicarbonate ions flow into the lumen; water follows by osmotic gradient. Stool softens, transit accelerates.
The pain pathway is separate and slower to develop. Intracellular cGMP gets pumped out to the submucosal space via MRP4 efflux transporters. On the other side, extracellular cGMP acts on colonic afferent nerve endings, reducing the firing threshold of visceral nociceptors. This is what produces the abdominal pain relief that distinguishes linaclotide from simple laxatives.
Linaclotide's active metabolite (MM-419447, formed by loss of the C-terminal tyrosine) retains full GC-C agonist activity. Both parent and metabolite are broken down within about an hour in intestinal fluid through disulfide bond reduction. Systemic absorption is negligible, below 0.1%. The entire therapeutic effect happens inside the gut lumen.
Linaclotide (Linzess) Benefits
- Linaclotide benefits center on dual-mechanism relief of both constipation and visceral pain in IBS-C and CIC.
- 33.7% composite responder rate (pain + stool frequency) for IBS-C at 290 mcg in the Chey et al. 26-week Phase 3 trial (n=800+)[1], versus 13.9% placebo. That gives an NNT of 5 to 8.
- Bowel movement improvement within 24 hours of the first dose. Phase 3 data and community reports both confirm this rapid onset, making it one of the faster-acting prescription options for chronic constipation.
- Visceral pain reduction through a distinct cGMP-mediated pathway. The laxative effect is only part of it. Extracellular cGMP modulates submucosal afferent nerve signaling, and pain scores separated from placebo by weeks 2 to 3 in IBS-C trials.
- Oral capsule, once daily, no injections or reconstitution. Linaclotide is one of the rare peptide therapeutics designed for oral delivery and stored at room temperature.
- Pediatric IBS-C approval (ages 7 and older) granted November 4, 2025, at 145 mcg daily. The 52-week safety dataset from NASPGHAN 2025 flagged a diarrhea rate of just 6.1%, lower than adult trials.
- Near-zero systemic exposure (<0.1% bioavailability), so off-target side effects are almost nonexistent. The drug stays in the gut.
Linaclotide (Linzess): Science vs Community Consensus
FDA-approved first-in-class GC-C agonist with strong Phase 3 RCT evidence for IBS-C and CIC.
Read the evidence (key study, limitations)
~34% composite responder rate for IBS-C (290 mcg) vs. 14–21% placebo; NNT 5–8. Dual mechanism: luminal fluid secretion (CFTR activation) + visceral pain reduction (extracellular cGMP modulation of afferent nerves).
Chey et al., Am J Gastroenterol 2012 (PMID 22986437): 26-week Phase 3 IBS-C RCT (n=800+); 33.7% responder rate vs. 13.9% placebo
NNT 5–8 means ~65% of IBS-C patients are non-responders; diarrhea in 14–20% of patients requires dose reduction; no published head-to-head RCT vs. plecanatide; long-term data (>26 weeks) limited in adults
Works rapidly for constipation relief but explosive diarrhea is the dominant complaint.
Read the reports (what users report 4, common issues 5)
Dose paradox widely reported: lower doses (72–145 mcg) often tolerated better than 290 mcg with similar constipation benefit for a subset. Non-response in ~30–40% of real-world users.
- Rapid onset: bowel movement improvement within 24–48 hours
- Abdominal pain and bloating reduction in IBS-C
- Once-daily oral dosing, no injections required
- Dose reduction to 72–145 mcg frequently achieves acceptable symptom control with less diarrhea
- Explosive/urgent diarrhea: often described as unpredictable and disruptive (especially first 1–2 weeks at 290 mcg)
- Strict 30-minute fasting window difficult to maintain consistently; missing it worsens diarrhea
- High cash price (~$683/month) without insurance or manufacturer savings card
- Non-response in a substantial minority (~30–40%) despite dose escalation
- Symptoms return within ~1 week of stopping: perceived as dependency
Science and community agree on core efficacy for IBS-C/CIC and the diarrhea side effect profile. Key divergence: FDA approves 290 mcg as the IBS-C dose, but community frequently downdoses to 72–145 mcg due to intolerable diarrhea: a dose reduction strategy the FDA label also supports as a fallback. Community also reports the dose paradox (lower = better for some) which is mechanistically explained by near-maximal GC-C receptor occupancy at 72–145 mcg.
Linaclotide (Linzess) Dosage Guide
| Level | Dose | Frequency |
|---|---|---|
| Beginner | 145 mcg | Daily |
| Moderate | 145 mcg | Daily |
| Aggressive | 290 mcg | Daily |
No vials, no syringes, no bacteriostatic water. Linaclotide is an oral capsule. Swallow it whole on an empty stomach, at least 30 minutes before eating. Set an alarm if that helps; the fasting window matters.
The 72 mcg dose covers CIC (adults) and pediatric functional constipation (ages 2 and older). The 145 mcg dose is for adult CIC and pediatric IBS-C (ages 7 and older). The 290 mcg dose targets adult IBS-C specifically.
If you can't swallow capsules, open them and sprinkle the beads onto room-temperature applesauce. Swallow immediately without chewing. They also work through NG or gastrostomy tubes mixed with water. Don't use hot food, don't chew the beads, don't store the mixture.
Store at room temperature (20 to 25 degrees C). No refrigeration needed.
One thing that catches people off guard: symptoms come back within about a week of stopping. This isn't dependency; it's just how local-acting drugs work. GC-C receptors don't desensitize, but they also don't stay activated once you stop providing the agonist.
Cycling
Linaclotide is intended for continuous daily use, not cycled. Clinical trials ran 12-26 weeks of uninterrupted dosing with sustained efficacy and no evidence of tachyphylaxis or tolerance. The FDA label does not specify a maximum treatment duration. Symptoms typically return within 1 week of discontinuation, as demonstrated in the 4-week randomized withdrawal phase of a Phase 3 IBS-C trial. Patients should continue taking linaclotide daily as long as the prescribing physician recommends.
Linaclotide is intended for continuous daily use: no cycling is required or recommended. GC-C receptors on luminal intestinal epithelial cells do not desensitize with chronic agonist exposure; no tachyphylaxis has been documented in 26-week Phase 3 trials or long-term observational data. Symptoms recur within ~1 week of cessation (confirmed in 4-week randomized withdrawal study), confirming sustained receptor engagement without downregulation. No on/off cycle is listed for it, which matches this.
- Symptom relapse despite consistent daily use suggests non-response (not tolerance): full response evaluation should occur at 12 weeks, not earlier
- Intolerable diarrhea not resolved by dose reduction is a reason to discontinue permanently, not to cycle off temporarily
Or use the universal Peptide Calculator for any peptide.
Linaclotide (Linzess) Protocols by Goal
Expected: Increased spontaneous bowel movement frequency; improved stool consistency; reduced bloating. Onset typically within 24–48 hours.
Monitor: Assess stool frequency and consistency at weeks 2 and 4. Check electrolytes if significant diarrhea occurs.
How to Use Linaclotide (Linzess)
- 1Step 1
Take one capsule by mouth once daily, at least 30 minutes before the first meal of the day. The best timing is immediately after waking, before getting out of bed.
- 2Swallow the capsule whole with water
Do not crush, break, or chew.
- 3Step 3
If swallowing is difficult, open the capsule and sprinkle the beads onto a tablespoon of room-temperature applesauce. Swallow the mixture right away without chewing the beads. Do not store the mixture or mix with hot food.
- 4Step 4
For tube-fed patients, the beads can be mixed with water and administered through a nasogastric or gastrostomy tube. Flush the tube with additional water afterward.
- 5Step 5
No reconstitution, no refrigeration, no syringe calculations. This is an oral peptide. The capsule contains the full dose (72, 145, or 290 mcg depending on your prescription).
- 6Step 6
Store capsules at controlled room temperature (20 to 25 degrees C). Excursions to 15 to 30 degrees C are acceptable. Do not freeze.
- 7Step 7
If a capsule is accidentally opened and the beads look clumped or degraded, discard it and use a fresh capsule.
Alternative Routes
No dose adjustment: same bead content, identical bioactive dose
Swallow bead/applesauce mixture immediately without chewing beads. Do not mix with hot food or liquids. Do not store mixture after preparation. Bead matrix is protease-resistant and must not be crushed.
No dose adjustment
Mix capsule beads in water and administer via tube. Flush tube with additional water after administration. Used in hospitalized or tube-dependent patients.
Linaclotide (Linzess) Stacking Protocols
Works With
Community-used adjunct for IBS-C: BPC-157 supports GI mucosal healing and motility via growth factor upregulation and NO signaling, complementary to linaclotide's secretory mechanism. No pharmacokinetic interaction (linaclotide is not systemically absorbed). Anecdotal IBS-C benefit reported in refractory cases.
α-MSH tripeptide with anti-inflammatory GI effects. Community-used alongside linaclotide in IBS-C patients with significant visceral inflammation. No clinical combination data; rationale is complementary mechanism (anti-inflammatory vs. pro-secretory).
Tight junction stabilizer with evidence in IBS and celiac disease. Community combines with linaclotide in IBS-C patients who have co-existing gut permeability concerns. No clinical combination data.
Avoid
Same GC-C agonist mechanism: concurrent use produces additive GI fluid secretion with no additional efficacy benefit. Switching between them is clinically rational; concurrent use is not.
Do not combineDifferent secretagogue (ClC-2 chloride channel activator) but overlapping intestinal secretory effect. Concurrent use risks additive diarrhea and excessive fluid secretion.
Do not combineOpioid receptor agonist that reduces GI motility and secretion: directly counteracts linaclotide's intended mechanism. Use negates the therapeutic purpose.
Do not combineEstimated Cost
Pricing updated 2026-04-09
Linaclotide (Linzess) Side Effects
The boxed warning comes first: linaclotide is contraindicated in children under 2 years of age. In neonatal mice, a single clinically relevant adult dose caused deaths from dehydration. Data on GC-C expression in children under 2 are too thin to rule that risk out. This is not a soft warning.
Diarrhea is the most common adverse effect, reported in 14 to 20% of patients across Phase 3 trials compared to 3 to 5% on placebo. It is dose-dependent, worst in the first 1 to 2 weeks (especially at 290 mcg), and typically improves as the GI tract adapts. The mechanism is straightforward: CFTR activation pulls fluid into the lumen, and the secretory effect doesn't always calibrate perfectly to each patient's GI capacity.
Community descriptions are blunter than the trial data suggests. The word "explosive" comes up frequently in r/ibs threads, along with reports of unpredictable urgency that disrupts daily routines. The practical workaround most users converge on is taking the dose immediately upon waking, before getting out of bed, so the urgency window happens during the morning routine.
Severe diarrhea requiring hospitalization has been reported in postmarketing surveillance. These rare cases sometimes involved dizziness, syncope, hypotension, or electrolyte abnormalities (hypokalemia, hyponatremia). Anyone on concurrent diuretics or ACE inhibitors should be monitored more closely for electrolyte shifts if diarrhea becomes persistent.
Other reported effects in clinical trials include abdominal pain, flatulence, abdominal distension, and headache, all at low rates. Nausea is rare.
The dose paradox is worth understanding. At 72 to 145 mcg, GC-C receptor occupancy is already near-maximal in many people. Going higher to 290 mcg increases luminal fluid secretion without proportionally improving constipation relief. If 290 mcg produces intolerable diarrhea, the FDA label supports stepping down to 145 or 72 mcg. Community users discovered this pattern independently; it now appears in roughly a third of user reports.
A practical note on timing: taking linaclotide within 30 minutes of food or with a high-fat meal significantly increases diarrhea rates per the PK data. The 30-minute fasting window is not optional.
Pregnancy status is Category C. No embryofetal toxicity was seen in animal studies, but human data is insufficient. Linaclotide is not absorbed systemically, which offers some reassurance, but prescribers should weigh the benefit against the uncertainty. Breastfeeding data is similarly limited, though negligible systemic absorption suggests low risk of infant exposure.
When to stop: persistent intolerable diarrhea that doesn't resolve with dose reduction, no improvement in stool frequency after 12 weeks, or any sign of GI obstruction.
Common Issues & Solutions
Explosive diarrhea at 290 mcg: FDA-supported dose reduction to 145 mcg is first-line response: many community users achieve equivalent constipation benefit at lower doses due to near-maximal GC-C occupancy at 72–145 mcg.
Unpredictable urgency: shift dosing to immediately upon waking before getting out of bed: the bowel response window is more predictable and less disruptive when the drug is taken before rising.
No effect despite correct timing: confirm strict 30-minute pre-meal fasting window; ingesting within 30 minutes of eating paradoxically increases diarrhea risk AND reduces constipation efficacy simultaneously (documented in PK study).
Bloating without constipation improvement: visceral pain and bloating response lags stool frequency improvement by 1–2 weeks (extracellular cGMP modulation of afferent nerves requires sustained GC-C activation). Give at least 4 weeks before concluding non-response.
No response at 12 weeks: responder/non-responder separation is evident by weeks 2–4; if neither pain nor stool frequency has improved by week 12, the drug is unlikely to work. Switch to plecanatide (lower diarrhea rate) or lubiprostone (different mechanism).
Ask AI about this page
Ask AI for a second opinion on Linaclotide (Linzess) dosing and side effects
Contraindications
- Children under 2 years of age: BOXED WARNING, risk of serious dehydration (a single clinically relevant adult dose caused dehydration deaths in neonatal mice)
- Known or suspected mechanical gastrointestinal obstruction
- Known hypersensitivity to linaclotide or any capsule excipients
- Pregnancy: Category C; insufficient human data, embryofetal toxicity not observed in animal studies but use only if benefit outweighs risk
- Breastfeeding: linaclotide and its metabolite are not absorbed systemically, but caution is advised due to limited data
- IBS-C in children under 7 years: safety and effectiveness not established (IBS-C is labeled for ages 7 and older)
Drug Interactions
- Proton pump inhibitors (omeprazole, lansoprazole): may alter capsule dissolution timing; clinical significance unclear but no dose adjustment required per FDA label
- Other secretagogues (lubiprostone, plecanatide): avoid concurrent use due to additive diarrhea risk and overlapping mechanisms
- Antidiarrheal agents (loperamide): may counteract linaclotide's therapeutic effect; concurrent use undermines treatment rationale
- Diuretics and ACE inhibitors: monitor for electrolyte imbalances if linaclotide-induced diarrhea is significant, particularly hypokalemia and hyponatremia
- Drugs with narrow therapeutic index requiring consistent GI absorption (warfarin, digoxin, levothyroxine): increased intestinal fluid could theoretically alter absorption kinetics; monitor levels
- Same GC-C agonist mechanism: concurrent use produces additive GI fluid secretion with no additional efficacy benefit. Switching between them is clinically rational; concurrent use is not.
- Opioid receptor agonist that reduces GI motility and secretion: directly counteracts linaclotide's intended mechanism. Use negates the therapeutic purpose.
Product Quality
FDA-approved brand-name drug (Linzess) manufactured by Ironwood Pharmaceuticals under full GMP requirements. Dispensed exclusively by licensed US pharmacies with valid prescription. No compounding market exists; counterfeiting is not a known concern for a regulated Schedule-uncontrolled oral prescription capsule.
- Obtain only through a licensed US pharmacy with a valid prescription
- Use the Ironwood/AbbVie manufacturer savings card: reduces cost to $30/month for commercially insured patients
- Online gray-market and international pharmacy products are unverified
- Store capsules at 20–25°C; excursions to 15–30°C permitted; do not refrigerate or freeze
- If capsule is accidentally opened, do not use degraded or clumped beads: obtain replacement capsule
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Symptom diary / IBS-SSS (Irritable Bowel Syndrome Severity Scoring System) | Baseline, weeks 2, 4, and 12 | IBS-SSS reduction >50 points = clinically meaningful response; FDA composite endpoint = ≥30% abdominal pain reduction + ≥1 additional CSBM/week for ≥6/12 treatment weeks |
| Basic metabolic panel (electrolytes: Na+, K+) | If significant or persistent diarrhea occurs (>3 loose stools/day for >3 consecutive days) | K+ 3.5–5.0 mEq/L; Na+ 135–145 mEq/L |
| Hydration assessment | First 2 weeks of initiation; any time diarrhea is significant | Not listed |
Quantifies IBS-C symptom severity (abdominal pain intensity/frequency, bloating, bowel satisfaction, stool consistency) to assess response and confirm responder status by week 12.
Diarrhea-induced hypokalemia and hyponatremia reported in rare postmarketing cases. Risk higher with concurrent diuretic use, renal impairment, or in elderly/pediatric patients.
Dehydration is the primary serious safety concern, especially in children (contraindicated <2 years) and elderly or renally impaired patients. Severe diarrhea cases have required hospitalization in postmarketing surveillance.
Linaclotide (Linzess) Before and After
Begin once-daily dosing on an empty stomach 30 minutes before breakfast. Increased bowel movements may occur within 24 hours. Some patients experience loose stools or diarrhea in the first few days as the gut adjusts to increased fluid secretion. This typically self-resolves.
Improvement in stool frequency and consistency is often measurable within the first week. Complete spontaneous bowel movements (CSBMs) increase. Abdominal bloating may begin to reduce. If diarrhea is persistent or severe, dose reduction (290 mcg to 145 mcg, or 145 mcg to 72 mcg) is appropriate.
Sustained improvement in bowel habits. Abdominal pain reduction becomes more apparent as extracellular cGMP accumulates and modulates visceral afferent nerve signaling. In Phase 3 IBS-C trials, significant separation from placebo in pain scores was evident by week 2-3.
Full therapeutic benefit established. In clinical trials, approximately 34% of IBS-C patients met the FDA composite responder endpoint (improvement in both pain and stool frequency) over 12 weeks. Benefits are sustained with continued daily dosing. No tolerance or dose escalation needed.
Long-term maintenance phase. A 26-week Phase 3 trial confirmed sustained efficacy without diminishing returns. Discontinuation leads to symptom recurrence within approximately 1 week, confirming the need for ongoing therapy. Annual reassessment with prescribing physician is recommended.
What to Expect
Days 1 to 3: GC-C receptor activation starts within hours of the first capsule. Most Phase 3 patients saw bowel movement improvement within 24 hours. Community reports confirm a strong first-day effect for many users, with urgency kicking in 1 to 3 hours after dosing. Others notice nothing for 2 to 3 days. Diarrhea, cramping, and flatulence tend to peak in this window, particularly at 290 mcg.
Week 1: Stool frequency picks up measurably. Complete spontaneous bowel movements (CSBMs) increase; stool consistency improves on the Bristol Stool Scale. Bloating may start easing. Diarrhea stabilizes for some users but remains problematic for others at the higher dose. Dose reduction requests are common at this point.
Weeks 2 to 4: Pain reduction becomes more noticeable. Phase 3 IBS-C trials showed significant separation from placebo in visceral pain scores by weeks 2 to 3. The extracellular cGMP pathway modulating afferent nerve signaling needs sustained activation to build up. Community users describe feeling "back to normal" during this stretch; a subset finds 145 mcg works as well as 290 mcg with fewer side effects.
Weeks 4 to 12: The responder/non-responder split becomes clear. Around 34% hit the FDA composite endpoint for IBS-C (pain reduction plus stool frequency gain). Benefits hold steady without dose escalation or tolerance. Non-responders typically recognize their status by weeks 4 to 8 and look for alternatives like plecanatide or lubiprostone.
Month 3 and beyond: Long-term maintenance. The 26-week Phase 3 trial confirmed sustained efficacy without diminishing returns. No tachyphylaxis or GC-C desensitization documented. Symptoms return within about a week of stopping (confirmed in the 4-week randomized withdrawal phase). Ongoing issues for long-term users are mainly cost (for uninsured patients) and occasional loose stools.
Detailed Timeline: Science vs Community
GC-C receptor activation occurs within hours of first dose. Luminal fluid secretion begins immediately, increasing transit speed. Bowel movement improvement observed within 24 hours in most Phase 3 patients.
Strong first-day effect common: many describe urgency within 1–3 hours. Others notice nothing for 2–3 days. Diarrhea is typically worst in this window, especially at 290 mcg.
Significant increase in complete spontaneous bowel movements (CSBMs) vs. placebo measurable by week 1 in Phase 3 data. Bristol Stool Scale type improves (softer, better-formed stools).
Most users notice clear improvement in bowel frequency. Bloating may begin to reduce. Diarrhea stabilizing for some; still problematic for others at 290 mcg. Many seek dose reduction at this point.
Significant separation from placebo in visceral pain scores by weeks 2–3 in Phase 3 IBS-C trials. Extracellular cGMP modulation of submucosal afferent nerve endings requires sustained receptor activation to accumulate.
Pain and bloating relief becomes more apparent. Many users describe feeling "back to normal." Diarrhea stabilizes. Subset of users find 145 mcg achieves equivalent results to 290 mcg with fewer side effects.
~34% composite responder rate (IBS-C, 290 mcg); ~21–25% above placebo for CIC (145 mcg). Benefits sustained without dose escalation or attenuation across 12-week trial period.
Clear responder/non-responder split. Non-responders typically recognize this by week 4–8 and seek alternatives. Responders report significant quality-of-life gains: less cramping, more predictable bowel habits.
26-week Phase 3 trial confirmed sustained efficacy without attenuation. No tachyphylaxis, dose escalation, or GC-C desensitization documented. Symptoms return within ~1 week of stopping (confirmed in 4-week randomized withdrawal phase).
Long-term users report stable, consistent benefit. Main ongoing issues are cost (for uninsured patients) and occasional loose stools. Annual prescriber reassessment recommended.
Pharmacokinetics
Source: Systemic half-life is not measurable: linaclotide plasma concentrations are below the limit of quantification after therapeutic doses (72-290 mcg). The peptide and its active metabolite MM-419447 are degraded within ~1 hour in the intestinal lumen through disulfide bond reduction. The drug has no meaningful systemic PK (FDA label, Section 12.3)
Molecular Profile
Is Linaclotide (Linzess) Legal?
Linaclotide (Linzess) is FDA-approved for three indications: IBS-C in adults (290 mcg, approved 2012), chronic idiopathic constipation in adults (72 and 145 mcg, approved 2012), and pediatric IBS-C in patients aged 7 and older (145 mcg, approved November 4, 2025). Pediatric functional constipation at 72 mcg is also an approved indication, for ages 2 and older since May 21, 2026 (ages 6 to 17 from June 2023).
Linzess is a prescription-only medication manufactured by Ironwood Pharmaceuticals (marketed with AbbVie). It is dispensed through licensed US pharmacies. No compounding market exists for this drug. It is not a controlled substance.
No generic version is available. Mylan holds ANDA 209564, but patent settlements block market entry until approximately 2029 for the 145 and 290 mcg strengths, and roughly 2031 for 72 mcg.
Linaclotide is not listed on the WADA Prohibited List. It has no ergogenic properties or systemic activity relevant to athletic performance.
This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting or changing any medication.
Who Should Consider Linaclotide (Linzess)
- Adults with irritable bowel syndrome with constipation (IBS-C): FDA-approved at 290 mcg daily
- Adults with chronic idiopathic constipation (CIC): FDA-approved at 72 mcg or 145 mcg daily
- Pediatric patients aged 2 and older with functional constipation: FDA-approved at 72 mcg daily
- Patients who have failed osmotic laxatives, fiber supplements, or other first-line constipation therapies
- IBS-C patients with significant abdominal pain who need both motility and analgesic benefits
Related Peptides
What Changed for Linaclotide (Linzess)
- Dosing
Corrected Oct 9, 2026: the linaclotide beginner tier is 145 mcg daily, the adult CIC dose; 72 mcg is a tolerability option, per the Linzess label.
Before: Beginner 72 mcg daily After: Beginner 145 mcg daily; 72 mcg stays a label option for CIC by presentation or tolerability
Source: Linzess (linaclotide) prescribing information (openFDA label record, SPL version 39, effective May 21, 2026) (opens in a new tab) · Saved copy
- Safety
Corrected Oct 7, 2026: the Linzess label contraindicates linaclotide under age 2, not under 6, and covers IBS-C from age 7, per the FDA label.
Before: Children under 6 years of age: BOXED WARNING; not recommended for IBS-C in patients aged 6 to 17 years After: Children under 2 years of age: BOXED WARNING; IBS-C in children under 7: safety and effectiveness not established (labeled for ages 7 and older)
What this does not mean: The label has said under 2 since August 2021. No new FDA safety action happened on this date; the page was out of date.
Source: Linzess (linaclotide) prescribing information (openFDA label record, SPL version 39, effective May 21, 2026) (opens in a new tab) · Saved copy
- Safety
Corrected Oct 7, 2026: the boxed dehydration warning covers children under 2, not under 6, per the current Linzess label (SPL version 39).
Before: The boxed warning comes first: linaclotide is contraindicated in children under 6 years of age. After: The boxed warning comes first: linaclotide is contraindicated in children under 2 years of age.
Source: Linzess (linaclotide) prescribing information (openFDA label record, SPL version 39, effective May 21, 2026) (opens in a new tab) · Saved copy
Peptide Schedule Research TeamReviewed Apr 7, 20266 Citations
References
- [1]Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety (Chey et al., Am J Gastroenterol 2012) (opens in a new tab)(n=800)PubMed (opens in a new tab)PubMed
- [2]FDA NDA 209564
Additional References
- A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation (Rao et al., Am J Gastroenterol 2012) (opens in a new tab)PubMed 22986440PubMed
- Linaclotide in chronic idiopathic constipation patients with moderate to severe abdominal bloating: a randomized, controlled trial (Lacy et al., PLoS One 2015) (opens in a new tab)PubMed 26222318PubMed
- A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation (Johnston et al., Curr Med Res Opin 2013) (opens in a new tab)PubMed 23198977Review
- LINZESS (linaclotide) capsules: FDA Full Prescribing Information (2025) (opens in a new tab)FDA Label
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Linaclotide (Linzess)?
Popular. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 500+. Community mentions on Reddit: ~500+ threads (r/ibs, r/Constipation). Open r/ibs (opens in a new tab).
486 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
High search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.